Clinical Relevance of Pseudomonas aeruginosa: A Master of Adaptation and Survival Strategies

Pseudomonas: Model Organism, Pathogen, Cell Factory

Volumn , Issue , 2008, Pages 25-44

  Høiby, Niels ^a   Johansen, Helle Krogh ^a   Moser, Claus ^a   Ciofu, Oana ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adaptation; Antibiotic therapy; Clinical relevance; Evolutionary implications; Lung conductive zones; Lung respiratory zones; Pseudomonas aeruginosa; Survival strategies

Indexed keywords

EID: 77950630705     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527622009.ch2     Document Type: Chapter

References (99)

1. Zimakoff, J., Høiby, N., Rosendal, K. and Guilbert, J.P. (1983) Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect, 4, 31-40.
2. Campa, M., Bendinelli, M. and Friedman, H. (1993) Pseudomonas aeruginosa as an Opportunistic Pathogen, Plenum Press, New York.
3. Stanier, RY., Palleroni, NJ. and Doudoroff, M. (1966) The aerobic pseudomonads: a taxonomic study. J Gen Microbiol, 43, 159-271.
4. Stover, CK., Pham, XQ., Erwin, AL., Mizoguchi, SD.,Warrener, P.,Hickey, MJ., Brinkman, FSL.,Hufnagle, WO., Kowalik, DJ., Lagrou, M., Garber, RL., Goltry, L., Tolentino, E., WestbrockWadman, S., Yuan, Y., Brody, LL., Coulter, SN., Folger, KR., Kas, A., Larbig, K., Lim, R., Smith, K., Spencer, D.,Wong, GKS.,Wu, Z., Paulsen, IT., Reizer, J., Saier, MH., Hancock, REW., Lory, S. and Olson, MV. (2000) Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature, 406, 959-964.
5. Ciofu, O. (2003) Pseudomonas aeruginosa chromosomal b-lactamase in patients with cystic fibrosis and chronic lung infection -mechanism of antibiotic resistance and target of the humoral immune response. APMIS, 111, 4-47.
6. Obritsch, M., Fish, DN., Maclaren, R. and Jung, R. (2004) National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993-2002. Antimicrob Agents Chemother, 48, 4606-4610.
7. Bodey, GP. (2005) Management of febrile neutropenia: current strategies. Clin Infect Dis, 40 (Suppl 4), s237-s358.
8. Kang, C.-I., Kim, S.-H., Park, WB., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M. and Choe, K.-W. (2005) Bloodstream infections caused by antibiotic-resistant Gramnegative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother, 49, 760-766.
9. Russell, JA. (2006) Management of sepsis. N Engl J Med, 355, 1699-1713.
10. Osih, RB., McGregor, JC., Rich, SE., Moore, AC., Furono, JP., Perencevich, EN. and Harris, AD. (2007) Impact of empiric antibiotic therapy outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother, 51, 839-844.
11. Høiby, N., Johansen, H.K., Moser, C., Song, Z.J., Ciofu, O. and Kharazmi, A. (2001) Pseudomonas aeruginosa and the biofilm mode of growth. Microb Infect, 3, 1-13.
12. Boucher, R.C. (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J, 23, 146-158.
13. Armstrong, D.S., Hook, S.M., Jamsen, K.M., Nixon, G.M., Carzino, R., Carlin, J.B., Robertson, C.F. and Gromwood, K. (2005) Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol, 40, 500-510.
14. Frederiksen, B., Koch, C. and Høiby, N. (1999) The changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients 1974-1995. Pediatr Pulmonol, 28, 159-166.
15. Høiby, N. (2006) P aeruginosa in cystic fibrosis patients resists host defenses, antibiotics. Microbe, 1, 571-577.
16. Miller, R.A. and Britigan, B.E. (1997) Role of oxidants in microbial pathophysiology. Clin Microbiol Rev, 10, 1-18.
17. Hull, J., Vervaart, P., Grimwood, K. and Phelan, P. (1997) Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax, 52, 557-560.
18. Mathee, K., Ciofu, O., Sternberg, C., Lindum, P.W., Campbell, J.I.A., Jensen, P., Johnsen, A.H., Givskov, M., Molin, S., Høiby, N. and Kharazmi, A. (1999)Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology, 145, 1349-1357.
19. Ciofu, O., Johanneson, M., Hermansen, N.O., Meyer, P. and Høiby, N. (2008) Regulation of the algT operon sequence in mucoid and non-mucoid P. aeruginosa isolates from 115 Scandinavian patients with cystic fibrosisDand in 88 in vitro nonmucoid revertants. Microbiology, 154 (pt1), 103-113.
20. Boucher, J.C., Martinezsalazar, J., Schurr, M.J., Mudd, M.H., Yu, H. and Deretic, V. (1996) Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA. J Bacteriol, 178, 511-523.
21. Bragonzi, A., Wiehlmann, L., Klockgether, J., Cramer, N., Worlizsch, D., Döring, G. and Tümmler,B. (2006) Sequence diversity of the mucoid mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology, 152, 3261-3269.
22. Song, Z.J., Wu, H., Ciofu, O., Kong, K.F., Høiby, N., Rygaard, J., Kharazmi, A. and Mathee, K. (2003) Pseudomonas aeruginosa alginate is refractory to Th1 immune, response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol, 52, 731-740.
23. Ciofu, O., Riis, B., Pressler, T., Poulsen, H.E. and Høiby, N. (2005) Occurrence of hypermutable P aeruginosa in cystic fibrosis patients is associates with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother, 49, 2276-2282.
24. Bjarnsholt, T., Jensen, P.Ø., Madsen, K., Andersen, C.B., Pressler, T., Givskov, M. and Høiby, N. (2007) The bacterial burden of the CFlung -uncovering the black box. J Cystic Fibrosis, 6, (Suppl 1), s19.
25. Bjarnsholt, T., Jensen, P.Ø., Rasmussen, T.B., Christophersen, L., Calun, H., Hentzer, M., Hougen, H.P., Rygaard, J., Eberl, L., Høiby, N. and Givskov,M. (2005) Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology, 151, 3873-3880.
26. Bjarnsholt, T., Jensen, P.-Ø., Burmølle, M., Hentzer, M., Haagensen, J.A.J., Hougen, H.P., Calum, H.,Madsen, K.G., Moser, C., Molin, S., Høiby,N. andGivskov,M. (2005) Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorumsensing dependent. Microbiology, 151, 373-383.
27. Jensen P.Ø., Bjarnsholt, T., Phipps, R., Rasmussen, T.B., Calum, H., Christoffersen, L., Moser, C., Williams, P., Pressler, T., Givskov, M. and Høiby, N. (2007) Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology, 153, 1329-1338.
28. Hoffmann, N., Lee, B., Hentzer, M., Rasmussen, T.B., Song, Z., Johansen, H.K., Givskov, M. and Høiby, N. (2007) Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary growth phase killing of P aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr / mice. Antimicrob Agents Chemother, 51, 3677-3687.
29. Kobayashi, H. (1995) Airway biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. J Infect Chemother, 1, 1-15.
30. Tateda, K., Comte, R.,Pechere, J.C., Kohler, T.,Yamaguchi, K.andVanDelden,C. (2001) Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother, 45, 1930-1933.
31. Döring, G. and Høiby, N. (2004) Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis, 3, 67-91.
32. Proesmans, M., Balinska-Miskiewicz, W., Dupont, L., Bossuyt, X., Verhaegen, J., Høiby, N. and De Boeck, K. (2006) Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis center. Eur Respir J, 27, 937-943.
33. Pressler, T., Frederiksen, B., Skov, M., Garred, P., Koch, C. and Høiby, N. (2006) Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection -a case control study. J Cystic Fibrosis, 5, 9-15.
34. Høiby, N., Frederiksen, B. and Pressler, T. (2005) Eradication of early Pseudomonas aeruginosa infection. J Cystic Fibrosis, 4, 49-54.
35. Döring, G., Conway, S.P., Heijerman, H.G.M., Hodson, M.E., Høiby, N., Smyth, A. and Touw, D.J. (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J, 16, 749-767.
36. Westh, J.B. (2001) Pulmonary Physiology and Pathophysiology, Lippincott Williams& Wilkins, Philadelphia, PA.
37. Permin, H., Koch, C., Høiby, N., Christensen, H.O., Møller, A.F. and Møller, S. (1983) Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother, 12 (Suppl A), 313-323.
38. Levy, J., Smith, A.L., Koup, J.R., Williams-Warren, J. and Ramsey, B. (1984) Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr, 105, 117-124.
39. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., WilliamsWarren, J., Vasiljev, K.M., Borowitz, D., Bowman, C.M., Marshall, B.C., Marshall, S. and Smith, A.L. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med, 340, 23-30.
40. Gibson, R.L., Emerson, J., McNamara, S., Burns, L.L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., Konstan, M.W., Moss, R., RetschBogart, G., Wagener, J., Waltz, D., Wilmott, R., Zeitlin, P.L. and Ramsey, B. (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med, 167, 841-849.
41. Geller, D.E., Pitlick, W.H., Nardella, P.A., Tracewell, W.G. and Ramsey, B.W. (2002) Pharmacokinetics bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122, 219-226.
42. Le Brun, P.P.H. (2001) Optimization of Antibiotic Inhalation Therapy in Cystic Fibrosis. Studies on Nebulized Tobramycin. Development of a Colistin Dry Powder Inhaler System. University of Groningen.
43. Jensen, T., Pedersen, S.S., Garne, S., Heilmann, C., Høiby, N. and Koch, C. (1987) Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother, 19, 831-838.
44. Valerius, N.H., Koch, C. and Høiby, N. (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet, 338, 725-726.
45. Cedergren, J., Follin, P., Forslund, T., Lindmark, M., Sundquist, T. and Skogh, T. (2003) Inducible nitric oxide synthase (NOS II) is constitutive in human neutrophils. APMIS, 111, 963-968.
46. Hassett, D.J., Cuppoletti, J., Trapnell, B., Lymar, S.V., Rowe, J.J., Yoon, S.S.,Hilliard, G.M., Parvatiyar, K., Kamani, M.C., Wozniak, D.J., Hwang, S.H., McDermott, T.R. and Ochsner, U.A. (2002) Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev, 54, 1425-1443.
47. Pedersen, S.S., Espersen, F., Høiby, N. and Jensen, T. (1990) Immunoglobulin-A and immunoglobulin-G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol, 28, 747-755.
48. Pedersen, S.S., Kharazmi, A., Espersen, F. and Høiby, N. (1990) Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun, 58, 3363-3368.
49. Goldstein, W. and Döring, G. (1986) Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis, 134, 49-56.
50. Bruce, M.C., Poncz, L., Klinger, J.D., Stern, R.C., Tomashefski, J.F. and Dearborn, D.G. (1985) Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis, 132, 529-535.
51. Ammitzbøll, T., Pedersen, S.S., Espersen, F. and Schiøler, H. (1988) Excretion of urinary collagen metabolites correlates to severity of pulmonary disease in cystic fibrosis. Acta Paediatr Scand, 77, 842-846.
52. Johansen, H.K. (1996) Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: Experimental studies in animals. APMIS, 104 (Suppl 63), 5-42.
53. Tiddens, H.A.W.M. (2002) Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol, 34, 228-231.
54. Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A.,Meyer, K.C., Birrer, P., Bellon, G., Berger, J., Weiss, T., Botzenhart, K., Yankaskas, JR., Randell, S., Boucher, R.C. and Döring, G. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest, 109, 317-325.
55. Høiby, N. (1977) Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl, 262(C), 3-96.
56. Haussler, S., Tummler, B.,Weissbrodt, H., Rohde, M. and Steinmetz, I. (1999) Smallcolony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis, 29, 621-625.
57. Haussler, S. (2004) Biofilm formation by the small colony variant phenotype of Pseudomonas aeruginosa. Environ Microbiol, 6, 546-551.
58. Rainey, P.B. and Travisano, M. (1998) Adaptive radiation in a heterogenous environment. Nature, 394, 69-72.
59. Wyckoff, T.J.O., Thomas, B., Hassett, D.J. and Wozniak, D.J. (2002) Static growth of mucoid Pseudomonas aeruginosa selects for non-mucoid variants that have acquired flagellum-dependent motility. Microbiology, 148, 3423-3430.
60. Hoffmann, N., Rasmussen, T.B., Jensen, P.O., Stub, C., Hentzer, M., Molin, S., Ciofu, O.,Givskov, M., Johansen, H.K. and Høiby, N. (2005) Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis [Correction]. Infect Immun, 73, 5290.
61. Spiers, A.J., Buckling, A. and Rainey, P.B. (2000) The causes of Pseudomonas diversity. Microbiology, 146, 2345-2350.
62. Lee, B., Haagensen, J.A.J., Ciofu, O., Andersen, J.B., Høiby, N. and Molin, S. (2005) Heterogeneity of biofilms formed by non-mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol, 43, 5247-5255.
63. Pedersen, S.S., Høiby, N., Espersen, F. and Koch, C. (1992) Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax, 47, 6-13.
64. Pedersen, S.S., Møller, H., Espersen, F., Sørensen, C.H., Jensen, T. and Høiby, N. (1992) Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis. APMIS, 100, 326-334.
65. Shah, P.L., Scott, S.F., Geddes, D.M. and Hodson, ME. (1995) Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med, 89, 499-502.
66. Brandt, T., Breitenstein, S., Vonderhardt, H. and Tummler, B. (1995) DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax, 50, 880-882.
67. Ratjen, F. and Tummler, B. (1999) Comparison of the in vitro and in vivo response to inhaled DNase in patients with cystic fibrosis. Thorax, 54, 91.
68. Anwar, H., Strap, J.L. and Costerton, J.W. (1992) Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother, 36, 1347-1351.
69. Anwar, H., Strap, J.L., Chen, K. and Costerton, J.W. (1992) Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin. Antimicrob Agents Chemother, 36, 1208-1214.
70. Smith, A.L., Fiel, S.B.,MayerHamblett, N., Ramsey, B. and Burns, J.L. (2003) Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration -lack of association in cystic fibrosis. Chest, 123, 1495-1502.
71. Borriello, G., Werner, E., Roe, F., Kim, A.M., Ehrlich, G.D. and Stewart, P.S. (2004) Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother, 48, 2659-2664.
72. Keren, I., Kaldalu, N., Spoering, A.,Wang, Y.P. and Lewis, K. (2004) Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett, 230, 13-18.
73. Moskowitz, S.M., Foster, J.M., Emerson, J. and Burns, J.L. (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol, 42, 1915-1922.
74. Haagensen, J., Klausen, M., Ernst, R.K., Miller, S.I., Folkesson, A., Tolker-Nielsen, T. and Molin, S. (2007) Differentiation and distribution of colistin-and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol, 189, 28-37.
75. Ciofu, O., Fussing, V., Bagge, N., Koch, C. and Hoiby, N. (2001) Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, b-lactamase activity and RiboPrinting. J Antimicrob Chemother, 48, 391-396.
76. Giwercman, B., Lambert, P.A., Rosdahl, V.T., Shand, G.H. and Høiby, N. (1990) Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in vivo selection of stable partially derepressed b-lactamase producing strains. J Antimicrob Chemother, 26, 247-259.
77. Giwercman, B., Meyer, C., Lambert, P.A., Reinert, C. and Høiby,N. (1992)High-level b-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob Agents Chemother, 36, 71-76.
78. Dibdin, G.H., Assinder, S.J., Nichols,W.W. and Lambert, P.A. (1996) Mathematical model of b-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released b-lactamases. J Antimicrob Chemother, 38, 757-769.
79. Denton, M., Littlewood, J.M., Brownlee, K.G., Conway, S.P. and Todd, N.J. (1996) Spread of b-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis unit. Lancet, 348, 1596-1597.
80. Bagge, N., Ciofu, O., Hentzer, M., Campbell, J.I.A.,Givskov,M. and Høiby,N. (2002) Constitutive high expression of chromosomal b-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother, 46, 3406-3411.
81. Jalal, S., Ciofu, O., Høiby, N., Gotoh, N. and Wretlind, B. (2000) Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother, 44, 710-712.
82. Saiman, L., Mehar, F., Niu, W.W., Neu, H.C., Shaw, K.J., Miller, G. and Prince, A. (1996) Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis, 23, 532-537.
83. WestbrockWadman, S., Sherman, D.R., Hickey, M.J., Coulter, S.N., Zhu, Y.Q., Warrener, P., Nguyen, L.Y., Shawar, R.M., Folger, K.R. and Stover, C.K. (1999) Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother, 43, 2975-2983.
84. Burns, J.L., VanDalfsen, J.M., Shawar, R.M., Otto, K.L., Garber, R.L., Quan, J.M., Montgomery, A.B., Albers, G.M., Ramsey, B.W. and Smith, A.L. (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis, 179, 1190-1196.
85. MacLeod, D.L., Nelson, L.E., Shawar, R.M., Lin, B.B., Lockwood, L.G., Dirks, J.E., Miller, G.H., Burns, J.L. and Garber, R.L. (2000) Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis, 181, 1180-1184.
86. Denton, M., Kerr, K., Mooney, L., Keer, V., Raijgoppaal, A., Browniee, K., Arundel, P. and Conway, S. (2002) Transmission of Colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol, 34, 257-261.
87. Moskowitz, S.M., Ernst, R.K. and Miller, S.I. (2004) PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol, 186, 575-579.
88. Bagge, N., Hentzer, M., Andersen, J.B., Ciofu, O.,Givskov,M. and Høiby,N. (2004) Dynamics and spatial distribution of blactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother, 48, 1168-1174.
89. Bagge, N., Schuster, M., Hentzer, M., Ciofu, O., Givskov, M., Greenberg, E.P. and Høiby, N. (2004) Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and b-lactamase and alginate production. Antimicrob Agents Chemother, 48, 1175-1187.
90. Oliver, A.,Canton, R., Campo, P., Baquero, F. and Blazquez, J. (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science, 288, 1251-1253.
91. Oliver, A., Baquero, F. and Blazquez, J. (2002) The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol, 43, 1641-1650.
92. Macia, M.D., Borrell, N., Perez, J.L. and Oliver, A. (2004) Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother, 48, 2665-2672.
93. Macia, M.D., Blanquer, D., Togores, B., Sauleda, J., Perez, J.L. and Oliver, A. (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistanceinPseudomonasaeruginosastrains causing chronic lung infections. Antimicrob Agents Chemother, 49, 3382-3386.
94. Ciofu, O., Petersen, T.D., Jensen, P. and Høiby, N. (1999) Avidity of anti-P. aeruginosa antibodies during chronic infection in patients with cystic fibrosis. Thorax, 54, 141-144.
95. Ciofu, O., Bagge, N. and Høiby, N. (2002) Antibodies against b-lactamase can improve ceftazidime treatment of lung infection with b-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection. APMIS, 110, 881-891.
96. Ciofu, O. (2003) Pseudomonas aeruginosa chromosomal b-lactamase in patients with cystic fibrosis and chronic lung infection -mechanism of antibiotic resistance and target of the humoral immune response. APMIS, 111, 4-47.
97. Yang, L., Haagensen, J.A.J., Jelsbak, L., Johansen, H.K., Sternberg, C., Høiby, N. and Molin, S. (2007) In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol, Epub.
98. Lee, B., Ciofu, O., Wu, H., Hoffmann, N., Høiby, N. and Molin, S. (2007) Phenotypic and biofilm forming differences of mucoid and non-mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J.Clin. Microbiol.
99. Smith, E.E., Buckley, D.G., Wu, Z.A., Saenphimmacjak, C., Hoffman, L.R., D'Argenio, D.A., Miller, S.I., Ramsey, B.W., Speert, D.P., Moskowwitz, S.M., Burns, J.L., Kaul, R. and Olson, M.V. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA, 103, 8487-8492.